The healthcare unicorn created by Spotify's founder: Neko Health's $499 full-body scan and the reconstruction of preventive medicine.

Neko Health: Not Selling "Health Checkups", But Rebuilding the Operating System of Preventive Medicine If you only understand Neko Health as "the Spotify founder started a $499 full-body scanning company", you will seriously underestimate it. What it really wants to do is not to recreate a high-end health checkup center, nor to package MRI, CT, and blood tests to sell them more attractively. It is trying to do something much harder: Redesign "how a healthy person should enter the healthcare system". The basic logic of traditional healthcare is: You feel unwell → Find a doctor → Examination → Diagnosis → Treatment. Neko wants to move the entry point forward: You feel great → Establish a health baseline → Continuous measurement → Discover changes → Early intervention. These two sets of logic seem to differ by just one "earlier". In reality, they represent completely different healthcare economic models. This is also why Daniel Ek and Hjalmar Nilsonne, since 2018, would rather spend years building their own hardware, software, and clinics, rather than simply purchasing existing equipment on the market. As of September 2026, Neko has completed over 100,000 scans, with more than 350,000 people registered or on the waiting list globally; in July, it completed a $700 million Series C funding round, with market reports valuing it at approximately $7 billion. On September 24, it officially opened its first clinic in SoHo, New York, priced at $499 per session. Neko Health What is truly worth studying is not how much it is currently worth. But rather: Why does capital believe that "redesigning health checkups" could be worth $7 billion? ──────────────── 1. Neko's most important innovation is not the scanner, but redefining the "healthcare customer" Hjalmar Nilsonne was almost born into the healthcare system. His grandfather practiced medicine in Stockholm, his father is a doctor, his mother is a psychiatrist, and his brother is also a doctor. But precisely because of this, he long did not want to enter the healthcare industry. He himself said that for the first 32 years, he was trying to stay "as far away from healthcare as possible": not out of disrespect for doctors, but because he constantly heard his parents talk about the lack of time in the healthcare system, administrative burdens, outdated equipment, and resource limitations. Later, he went into energy, AI, and engineering startups. In 2018, Daniel Ek suddenly DM'd him on Twitter, hoping to rethink healthcare together. The two were not even really familiar before. The question Daniel Ek raised is very important: If there were no healthcare system in the world today, and we designed it from scratch, would we design it the way it is now? Most likely not. The modern hospital system is extremely good at: Saving lives after a heart attack; Repairing fractures; Treating infections; Performing surgery and drug treatment after tumors appear. But it was not inherently designed to: Establish a continuous biological data model for a person who considers themselves healthy every year. This is the gap that Neko has identified. ──────────────── 2. Today's healthcare actually has a very strange economic problem Cars can be regularly maintained. Airplanes have preventive maintenance. Data center servers are continuously monitored. Factory equipment collects sensor data in real-time. But the world's most expensive and complex asset— The human body Often still adopts: "Fix it when it breaks." Why? It is not that the medical community does not know that prevention is important. The real problem is: The payment, equipment, organization, and doctor time in the healthcare system are not designed around the continuous monitoring of large healthy populations. This is especially evident in the United States. The strongest revenue system for hospitals has long revolved around: Procedure; Treatment; Diagnosis; Reimbursement. That is: What treatment was done, how much insurance reimburses. And "this person will not get sick in the next ten years" is, on the contrary, very difficult to form the same clear revenue under the traditional fee-for-service model. This is called: Incentive Misalignment. ──────────────── 3. What Neko really wants to change is the timeline of healthcare A large amount of resources in traditional medicine is concentrated on: Disease Stage. Neko hopes to move forward to: Risk Stage. Even further to: Baseline Stage. These are three completely different concepts. For example, hypertension. The traditional system might wait until: Hypertension is accidentally discovered during a health check. In worse cases: It is only discovered after a cardiovascular event occurs. If continuous data over several years is available, one can see: Blood pressure; Arterial stiffness; Blood lipids; Visceral fat; Blood sugar; Weight; Activity level How they change. The medical value begins to upgrade from: "Are you normal today?" To: "What direction are you moving in?" This change is extremely important. ──────────────── 4. Therefore, the most valuable data in future precision medicine may not be a single checkup, but your "time series" Currently, most health check reports are: A single Snapshot. For example: LDL = 120. The problem is: 120 itself has limited information. If you have had: 80 → 86 → 94 → 108 → 120 over the past five years, The meaning is completely different. If another person has: 160 → 150 → 140 → 128 → 120, Although both have the same number today, Their health trajectories may be completely opposite. This is: Longitudinal Data. In the future, the greatest value of AI in healthcare may not be having a single 1000-item indicator. But having a person: 5 years; 10 years; 20 years Of continuous multimodal data. This is the true personal health model. ──────────────── 5. So Neko's real product may not be the "$499 scan" $499 is just the entry point. What may truly form long-term value is: Personal health data assets. The first time entering Neko: Establish Baseline. The second year: Discover Delta. The third year: Discover Trend. The fifth year: Start establishing an individual's own normal range. This means that medical judgment can shift from: Population Average To: Personal Baseline. This may be the most important step in precision medicine. ──────────────── 6. Why does Neko have to build its own machines? This is the key business question to understand this company. Ordinary entrepreneurs entering the healthcare checkup field usually find the most reasonable method is to: Purchase ready-made MRI; Buy ultrasound equipment; Procure blood testing equipment; Buy software; Rent a clinic; Repackage the experience. This is the fastest way. Neko, however, chose the slowest and most expensive path: To build its own medical equipment. Since 2018, the company has been developing its own imaging, optical sensing, and cardiovascular measurement systems internally; the publicly available products now include technologies such as Derma, Spectrum, and Echo. Neko Health Why? Because if all your core equipment comes from others: Your cost structure is also someone else's; The detection speed is also someone else's; The equipment form is also someone else's; The upgrade cycle is also someone else's; The data format is also someone else's. You can only optimize: Decoration and service. ──────────────── 7. This is the same entrepreneurial logic as Tesla, SpaceX, and Apple The so-called: Vertical Integration. Why does Tesla do its own: Batteries; Software; Electronic architecture; Supercharging; Manufacturing? Because if it completely relies on the traditional automotive supply chain, It can only produce another traditional car. Why does SpaceX make its own engines, rockets, and many components? Because the traditional aerospace supply chain's: Prices; Speed; Manufacturing methods Cannot achieve its goals. Why does Apple long control: Chips; Operating systems; Hardware; Retail; Software ecosystem? Because the ultimate user experience depends on the entire system. What Neko is doing in healthcare is similar. It is not asking: "What equipment is available on the market?" It is asking: "What machines do we need to provide a healthy person with a lot of high-quality information in one hour?" If the machines do not exist: Build them yourself. ──────────────── 8. This is why Neko's real moat is not "the clinic is beautifully decorated" A beautiful clinic is very easy to replicate. A company that has: Medical equipment R&D; Clinical validation; Hardware manufacturing; AI; Software; Doctor teams; Physical operations; Patient workflows Is not so easy to replicate. This is also why Nilsonne emphasizes that Neko internally allows: Physicists; Optical engineers; Machine learning researchers; Doctors; Industrial designers To work together. This may seem inefficient. But real large-scale system innovations often occur at: The intersection of disciplines. ──────────────── 9. The iteration speed of software companies and the culture of medical device companies are inherently in conflict This is one of Neko's biggest organizational challenges. The culture of software engineers is: Ship. Discover problems. Update. Release Version 2 tomorrow. The logic of medical hardware engineers, however, is: If the equipment has problems, It may harm patients. So it must be: Verified; Documented; Repeatedly tested; Regulated. Doctors have a third culture. Doctors first ask: What is the Clinical Utility? These three teams naturally speak three different languages. So what Neko may find difficult to replicate is not a specific Sensor. But: Integrating healthcare, software, and hardware into one organization. ──────────────── 10. Why is the price of $499 extremely important? The price is actually one of the core technical indicators of Neko's business model. If a preventive checkup costs: $10,000, It becomes: Luxury Medicine. Customers may be: Millionaires; Billionaires; High-end Concierge Medicine users. The market is very small. If the price is: $499, The nature begins to change. It gradually enters: The consumption range that ordinary middle to high-income consumers Can consider once a year. The current official price of Neko in New York is: One hour for $499, and supports HSA/FSA payments, but currently does not participate in commercial health insurance networks. Neko Health Prices range from: $10,000 → $500 It's not simply a 95% reduction. It means: The market category has changed. ──────────────── Eleven, this is one of the most important innovations in the history of technology: Cost Curve Innovation Many great companies did not create something that did not exist before. They turned: Originally expensive things Into: Widely accessible. Ford did not invent the car. It changed: The cost of car manufacturing. AWS did not invent servers. It changed: The cost of accessing computing resources. Spotify did not invent music. It changed: The way music is obtained. If Neko ultimately succeeds, What it really creates is not a "health check." But possibly: Industrialized, standardized, large-scale high-density preventive checks. ──────────────── Twelve, what really matters is not $499, but whether it can continue to decrease in the future Nilsonne's long-term goal is not: To always operate high-end boutique clinics. But rather: To continuously lower costs. This is extremely important. Because the biggest limitation in the healthcare industry has never been: Whether there are better checks in the world. But rather: Who can afford it. If in the future: $499 → $300 → $200 → $100, The nature of the market will change again. When prices are low enough: Employers; Insurance; Public health systems May start to seriously consider large-scale procurement. At that time, Neko will truly upgrade from: Consumer Health Company To: Healthcare Infrastructure. ──────────────── Thirteen, why is a 75% repurchase rate more important than valuation? Neko currently discloses: After the first check, about 75% of users will book and prepay for the next scan; After completing the second scan, about 80% will book a third. PR Newswire If this number can be maintained in the long term, it is very important. Because it means: Users do not see the product as: "A cool technology to experience once in a lifetime." But rather: Recurring Health Behavior. Although it is not formally a traditional SaaS Subscription, The economic structure begins to resemble a subscription. After acquiring customers for the first time, They will continue to consume every year. ──────────────── Fourteen, truly great business models in healthcare often have both high trust and high repurchase Netflix can be canceled. Fitness apps can be ignored. But if a medical product gains user trust, The Switching Cost may be very high. Because the company starts to have: Historical checks; Personal baselines; Doctor explanations; Long-term trends. If you switch to another company in the second year, The new institution does not have: Your past. This creates: Data Gravity. The longer the time: The higher the value. The cost of users leaving also increases. ──────────────── Fifteen, this may become Neko's true biggest moat: not AI, but longitudinal dataset Today any company can buy: GPT; Claude; Medical models. So AI itself is becoming increasingly difficult to serve as a permanent barrier. However, if a company has: 1 million people × 10 years × once a year of standardized: Skin; Cardiovascular; Metabolic; Blood; Body composition; Wearable data; Medical outcomes, This is a very different asset. Especially if it knows: Whether a certain abnormality later developed into a disease. Then it forms: Outcome-labelled Longitudinal Dataset. A long-term health database with real outcome labels. This is extremely important for future medical AI. ──────────────── Sixteen, truly valuable medical data is not "more," but has Outcome A typical health database can tell AI: This person's LDL is 160. What is truly more valuable is: What happened ten years later? Were there: Heart attacks; Strokes; Diabetes; Heart failure? What happened after treatment? This is called: Clinical Outcome Data. What AI really wants to learn is: Input → Outcome. If Neko can establish this closed loop, What it ultimately possesses is not just clinic business. But rather: Disease prediction infrastructure. ──────────────── Seventeen, this is also why Neko may have more strategic value than ordinary "full-body scan companies" Today, the market already has: Prenuvo; Function Health; Ezra; Fountain Life and other different preventive medical models. But the routes are not entirely the same. Some rely on: MRI. Some rely on: A large number of Lab Tests. Some rely on: Concierge Medicine. One of Neko's most unique routes is: Building measurement hardware + physical clinics + clinical interpretation. In other words, it simultaneously controls: Data Generation; Data Interpretation; Consumer Experience. This is a heavy business model. But once successful, It is also harder to be purely replicated by software. ──────────────── Eighteen, why might "heaviness" in the healthcare field become an advantage? In the past decade, VCs have favored: Asset-light. Light assets. Because: Fast expansion; High gross margins; Low capital requirements. But as AI becomes stronger, Pure software becomes increasingly easy to replicate. Thus, investment value may shift back to: Hard-to-build Systems Laboratories; Robots; Medical devices; Manufacturing; Clinic networks; Infrastructure. Because: Code is becoming cheaper, Real-world execution is becoming scarce. Neko happens to stand at the forefront of this shift. ──────────────── Nineteen, the location of the New York SoHo store itself is a business strategy Neko's first clinic in the U.S. is not located in a traditional medical park. But at: 300 Lafayette Street, SoHo. Next to: Retail; Fashion; Dining; Consumer brands. This is not just for aesthetics. But to change users' psychological categorization of healthcare. The psychological implication of a traditional hospital is: I am sick. Neko wants consumers to feel: This is a health behavior I actively engage in every year. The difference between the two is enormous. ──────────────── Twenty, this is actually transforming Healthcare into Consumer Experience What Apple excels at is not just chips. It is: Consumers willingly walk into the Apple Store. One of the biggest problems with traditional hospitals is: People do not want to go. If Neko ultimately achieves: Consumers willingly make appointments; Willing to return every year; Even feel this is part of "taking care of themselves," Then what it changes is: Healthcare Engagement. In preventive medicine, this may be more important than any single sensor. Because the most advanced checks, If no one is willing to do them, The medical value remains zero. ──────────────── Twenty-one, but here we must start discussing the most important question: Is more testing really better? The answer is: Not necessarily. This is the aspect that the entire preventive medical industry should remain clear about. Any large-scale screening has: False Positives; Incidental Findings; Overdiagnosis; Overtreatment. That is: False positives; Incidental findings; Overdiagnosis; Overtreatment. The more tests an asymptomatic person undergoes, Statistically, the probability of at least one abnormal result appearing naturally increases. Abnormalities do not always equal: Disease. Disease does not always mean: The earlier the treatment, the better. ──────────────── Twenty-two, the premise of "early detection and early treatment" in medicine actually has a hidden condition This statement only holds true if the following logic is valid: Taking treatment after early detection really improves the final outcome compared to late detection. It sounds self-evident. But in medicine, it must be proven by research. Some cancers: Early screening can indeed reduce mortality. Thus forming mature: Breast cancer; Cervical cancer; Colorectal cancer; Specific high-risk lung cancer screening guidelines. But not all abnormalities that could be detected have such evidence. This is the core of Screening Science. ──────────────── Twenty-three, therefore, "how many diseases were discovered" cannot alone prove the effectiveness of a screening system This is a particularly important point. Neko's published 2025 data from Sweden states: About 4% of members were found to have significant diseases requiring medical treatment; About 2% showed early risks that could be managed through lifestyle and monitoring; Among the population with existing result data, about 1% of asymptomatic members were found to have serious, potentially life-threatening diseases. Neko Health These numbers are very worthy of study. But they cannot alone prove: "Doing Neko every year for all healthy adults will definitely reduce mortality." These are two completely different conclusions. Neko itself also clearly states in its 2024 data report: These are real-world observational data, Not scientific research with a control group. Neko Health This sentence is very important. ──────────────── Twenty-four, why does this not weaken Neko, but rather point out its true next phase of tasks? First phase: Prove that the equipment can work. Second phase: Prove that consumers are willing to pay. Third phase: Prove that clinically actionable findings can be discovered. The fourth phase is the most difficult: Prove long-term improvement in Health Outcomes. For example: Is cardiovascular mortality reduced? Is the proportion of late-stage tumors reduced? Are major diseases treated earlier? Is it possible to reduce long-term medical costs? What are the costs of examinations and treatments caused by false positives? Only after this layer is established, can Neko truly complete the leap from: high-end preventive medical products to: evidence-based medical infrastructure. ──────────────── 25. Do not confuse Neko with "whole-body CT" This point must be clarified. The U.S. FDA has always been very cautious about whole-body CT scans for healthy asymptomatic individuals, one important reason being: CT uses ionizing radiation and may lead to a large number of incidental findings and further examinations. The FDA currently states that there is no evidence that the overall benefits of whole-body CT scans for asymptomatic healthy individuals outweigh the risks. U.S. Food and Drug Administration But: Neko is not a CT. Nor is it a traditional whole-body MRI. Its current U.S. scans are clearly labeled: radiation-free, with the core combination being optical imaging, skin imaging, cardiovascular measurements, blood indicators, body composition, etc. Neko Health So the radiation risks of CT cannot simply be applied to Neko. However: The statistical issues of overdiagnosis and false positives still exist. ──────────────── 26. Neko's smartest handling of this issue is not to throw patients a PDF Many traditional health check-up problems are not: too many examinations. But rather: no one explains after the examinations. Patients receive: tens of pages of reports. See a few red arrows. Then Google. Then anxiety. One of Neko's design focuses is: to have clinical doctors explain on the spot after measurements are completed. If needed, internal cardiac or skin specialist teams will further review and assist with referrals. Its U.S. official website also clearly states that specialist follow-up is included in the service. Neko Health This is important. Because: Screening must be connected to the Clinical Pathway. Otherwise, it can only generate data. It cannot create medical value. ──────────────── 27. The most common mistake in medical entrepreneurship: mistaking "more data" for "better healthcare" This is also a phrase that all health entrepreneurs should remember. 1,000 indicators, are not necessarily more valuable than 50 indicators. The key is: Which indicators can change decisions? Which abnormalities require action? Which changes are just noise? This is: Actionability. The real value formula of medical data is not: Data Volume. But should be closer to: Data × Accuracy × Clinical Actionability. Without the last item, the more data there is, the more noise it may even create. ──────────────── 28. Why can't the doctor aspect of Neko be easily removed? Many AI medical entrepreneurs imagine: In the future, after examinations, AI will automatically generate answers. Theoretically, this has the lowest cost. But real medical decision-making includes: probability; age; family history; symptoms; patient preferences; medical guidelines; risk tolerance. The same indicator, means different things for different people. So at least at the current stage: AI is more suitable for: Measurement + Pattern Detection + Decision Support. Doctors are responsible for: Context + Judgment + Responsibility. Neko's current model precisely combines the two. ──────────────── 29. True AI healthcare should not be about "replacing doctors with AI," but redistributing doctors' time This is a very important understanding. If AI can automatically complete: measurements; image recognition; risk sorting; report organization; historical comparisons; then doctors do not need to spend 20 minutes: finding data. They can spend their time on: explanations; judgment; patient communication; interventions. This could be the most realistic productivity revolution of AI in healthcare: allowing doctors to do only what doctors should do. ──────────────── 30. The real huge business opportunity for Neko in the future may not be B2C, but B2B2C Today: Consumers pay $499 themselves. In the future, if data proves: annual screenings can significantly reduce expensive diseases, who has the most motivation to buy? Employers. Insurance companies. The government. Why? Because they truly bear: long-term medical costs. Assuming: Preventive testing for 10,000 employees costs: $5M. If it can avoid: $15M in major disease and hospitalization costs in the long run, then corporate insurance plans have the economic incentive to purchase. At that point, the business model will change completely. ──────────────── 31. The business formula that Neko truly needs to prove is Preventive ROI It can be written as: **Early Detection Savings • Productivity Gains − Screening Cost − False Positive Cost − Follow-up Cost** If it ultimately results in a positive number, scaling up will have economic significance. This is much more important than: "Users feel the experience is great." Once this model is established, payers will upgrade from: individual wallets to: institutional healthcare budgets. That would be the truly huge market. ──────────────── 32. Why is the U.S. both Neko's biggest opportunity and the most challenging market? The U.S. has the highest healthcare spending in the world. This means: there is a huge potential for savings. At the same time, consumers have already become accustomed to: out-of-pocket wellness; concierge medicine; high-end lab testing; wearables. So $499 is not outrageous. On the other hand: The U.S. has the world's most complex: insurance networks; referral systems; state licenses; liability risks; data privacy; healthcare regulations. This is also why Neko's expansion in the U.S. is not simply about copying its Swedish stores. New York is just the first step; the company has currently listed Miami, Washington D.C., and San Francisco as the next phase markets. Neko Health ──────────────── 33. Moreover, the data privacy issues in the U.S. are more complex than the promotional language Neko emphasizes that users can control their health data. But there is a very noteworthy detail in the U.S. legal structure: Neko's U.S. Clinic Privacy Notice clearly states that because it currently does not participate in health insurance plans and its main services are not covered by insurance, its clinics are currently not HIPAA-defined covered entities. The company also states that it has still established privacy and security controls on its own. Neko Health This distinction is very important. "Protecting data like a healthcare institution" and "Legally being a HIPAA Covered Entity" are not the same thing. This is also an increasingly important regulatory issue for the U.S. digital health industry in the future. ──────────────── 34. Neko's most dangerous competitor may not be another clinic Many people will ask: Who will win, Neko or Prenuvo? This may not even be the most critical question. Long-term, truly strong competitors may include: Apple; Google; Amazon; large hospital networks; insurance companies. Why? Because the data needed for future preventive medicine includes: daily sleep; heart rate; exercise; blood sugar; weight; blood pressure; laboratory tests; medical imaging; treatment records. Apple Watch already has: continuous data. Neko mainly has: high-density clinical snapshots. The truly powerful system is: the combination of both. ──────────────── 35. This is also why Neko has already started integrating wearables The 2026 financing announcement specifically mentioned: The new Neko Scan has added: wearable device integration; body composition analysis. Neko Health This is not an additional feature. It represents a significant change in product direction: from: once-a-year check-ups. to: 365 days of health data + one high-precision clinical calibration. This could form a true: digital twin. ──────────────── 36. In the future, your "health digital twin" may be more important than your medical records Traditional electronic health records document: your past illnesses. In the future, personal health systems may record: your body's changes. Traditional medical records are: reactive records. The future should be: predictive models. It may know: your blood sugar is worsening; visceral fat is increasing; blood pressure baseline is rising; a mole is changing; cardiovascular indicators are deviating from their historical range. The true value of AI is: to identify: trajectories. trends. ──────────────── 37. The true endgame of future healthcare may be continuous prevention Currently: going to the hospital is an event. In the future: health management may become a process. Wearables: continuous monitoring. Clinics like Neko: periodic high-precision calibrations. AI: continuous analysis. Doctors: interventions at key points. Medications or lifestyle interventions: dynamic adjustments. Thus, healthcare is gradually shifting from: episodic care to: continuous care. This could be one of the biggest structural changes in healthcare in the next twenty years. ──────────────── 38. Why has GLP-1 suddenly made preventive medicine more valuable? In the past, it was discovered: obesity risk; Insulin resistance; Metabolic abnormalities. What doctors can often do is: Recommend exercise; Control diet. Today we see: GLP-1 class drugs. This means: The interventions that can be implemented after testing are becoming stronger. The same logic may occur in the future for: Alzheimer's disease; Cardiovascular diseases; Tumors; Genetic diseases. This is very important: The value of diagnostics depends on therapeutics. If a disease is discovered but cannot be treated, the value of early screening is limited. The stronger the treatment capability, the higher the value of early detection. ──────────────── Thirty-nine, so AI pharmaceuticals and preventive healthcare are actually two ends of the same industry chain. Upstream: Identify risks. Midstream: Predict diseases. Downstream: Precise treatment. If in the future AI helps humanity obtain: More targeted drugs; Personalized medications; Gene therapy; Precision immunotherapy, the healthcare system will increasingly need: Earlier detection of patients. Thus: AI Drug Discovery will in turn enhance: Preventive Diagnostics in economic value. This is the second-order effect between industries. ──────────────── Forty, why is capital willing to give Neko a valuation of $7 billion? It is not because: A scanner is worth $7 billion. What capital is really betting on are four things. First: Can Neko further reduce the $499? Second: Can the stores be industrially replicated? Third: Can the repurchase rate be maintained in the long term? Fourth, and most importantly: Can long-term data form a medical network effect? If it is just: A beautiful health check center, $7 billion is very expensive. If it ultimately becomes: Hundreds of clinics; Millions of long-term users; Proprietary medical equipment; A globally standardized health database; An AI disease prediction platform, then it is a completely different company. This is the valuation logic of Venture Capital: What is bought today is not: Revenue. But: Future Market Structure. ──────────────── Forty-one, but Neko's biggest risk is also very clear. It must simultaneously prove five very difficult things: Medically effective. Economically sustainable. Equipment can be mass-produced. Stores can be replicated across countries. The long-term benefits of large-scale screening outweigh the harms. Any failure in one of these will limit its ultimate scale. Therefore, Neko is a very typical: Execution-heavy Company. It is not about completing the software and replicating it globally. It must build in one city, one store, one regulatory market. ──────────────── Forty-two, this is also why it could be great, but also very difficult. The scale of a pure internet company is: Server expansion. Neko's scale includes: Buildings; Equipment; Doctors; Nurses; Hardware maintenance; Laboratories; Regulation; Referrals; Customer service. So it can never be like Spotify: Serving another hundred million people overnight. But conversely: This complexity itself also creates a moat. Once others discover the market, it does not mean they can replicate it the next day. This is called: Operational Moat. ──────────────── Forty-three, what entrepreneurs should really learn is: do not simply understand "old industries are inefficient" as "they are very stupid." The healthcare industry is slow, not because doctors do not understand the internet. Many times it is because: Life safety; Regulation; Payers; Liability risks; Conflicts of interest make change extremely difficult. So the most dangerous idea for a Healthcare Startup is: "These hospitals are too backward; we can solve it with an app." Neko, on the other hand, adopts a more mature route: Since the original system cannot be easily changed, then: Rebuild a complete experience from outside the system. This is the Tesla-like approach. ──────────────── Forty-four, what does "the Apple of the medical field" really mean? It is not: Stores like Apple Stores. What is truly worth learning are Apple's four capabilities: Control hardware. Control software. Control distribution. Control user experience. Neko is trying to add a fifth layer: Control Clinical Workflow. If these five layers can truly run smoothly, then it deserves to be called: Healthcare Apple. It is not just about decorating it to look whiter, and calling it Apple. ──────────────── Forty-five, what Neko is ultimately selling may not be checks, but a "sense of certainty." One of the biggest pain points of medical consumption is: Uncertainty. Am I healthy? What does this number mean? What should I do? Neko centralizes: Checks; Analysis; Doctor explanations; Follow-up paths to be completed in about an hour. So what users are really paying $499 for is not just: Data. But also: Clarity. Knowing where they are now, and what to do next. This is a very strong consumer value proposition. ──────────────── Forty-six, but truly top-tier medical companies ultimately cannot just sell "peace of mind." If in the long term it is only about: Making healthy people feel more at ease, the market will still be limited. The real endgame must be: Changing medical outcomes. Fewer: Heart attacks; Strokes; Late-stage cancers; Irreversible metabolic diseases. Longer: Healthspan. Lower: Lifetime medical costs. Only by achieving this level, can Neko truly complete its grandest story: Not: A new health check that high-end consumers like. But: Redesigning preventive healthcare. ──────────────── Forty-seven, from an entrepreneurial perspective, what is most worth learning from Neko is not that it entered healthcare, but that it chose to "redefine the cost structure." Many startups simply: Change the UI of an old product. Entrepreneurs who can truly create large companies often do: Cost Curve Reset. Tesla: Recalculating the cost of electric vehicles. SpaceX: Recalculating launch costs. AWS: Recalculating server costs. Spotify: Recalculating music distribution costs. If Neko succeeds: It recalculates the cost of high-density preventive medical checks. When entrepreneurs look for big opportunities, they can ask: What is something that only 1% of people can enjoy today, and if the cost drops by 90%, would suddenly become a mass market? This is a very effective question for finding large industries. ──────────────── Forty-eight, the real framework for investing in companies like Neko cannot just look at "the healthcare market is large." Healthcare TAM is certainly huge. This is meaningless. What should really be focused on are: Single store scanning volume; Equipment depreciation; Doctor utilization; Customer acquisition cost; Gross margin on first scans; Repurchase rate; Customer lifetime revenue; Severe abnormal referral rate; False Positive Rate; Store Payback Period; Speed of replication in new cities. Especially: How many people each device can stably handle per day. Because for physical healthcare companies: Throughput is like: Server Capacity for software companies. ──────────────── Forty-nine, companies that truly disrupt healthcare must ultimately win three battles simultaneously. The first battle: Technology. Measure faster, more accurately, and cheaper. The second battle: Trust. Patients and doctors trust you. The third battle: Economics. The larger the scale, the better the economic model. Most Healthcare Startups can only win one or two battles. Neko's valuation is actually betting: It can win all three battles simultaneously. ──────────────── Fifty, what is most worth remembering about Neko is not the $499. What is truly worth remembering is: It has re-asked a very old question: Why must healthcare wait until people are sick before it starts working? In the past, this question was difficult to solve. Because: Sensors were expensive; Medical imaging was expensive; Data storage was expensive; AI was immature; Consumers did not have wearables; Computing power was insufficient. Today, these constraints are simultaneously decreasing. Thus: The previously uneconomical healthcare model, may for the first time become economical. This is the real technological revolution. Technological revolutions are rarely just because: "A new machine was invented." More importantly: A previously unfeasible business system suddenly becomes feasible. ──────────────── The most memorable sentence The most important aspect of Neko Health is not whether it can measure more things in an hour. But it represents a shift in the medical paradigm: From treating diseases to continuously understanding the body. The core system of 20th-century healthcare was: Hospitals. 21st-century healthcare may gradually see the emergence of a second system: Continuous data + AI + periodic high-precision testing + doctor intervention. Hospitals will not disappear. Emergency care will not disappear. Surgery will not disappear. But if this system matures, patients facing hospitals may increasingly be less in the: "Already broken" stage. And more diseases will be discovered: When there is still time to change. This is the real story that makes Neko worth a $7 billion capital bet. But the capital story must ultimately pass the strictest test of medicine: Not how many abnormalities were discovered, Not how many people are in line, And not how beautiful the clinic design is, But whether it can prove in ten years: That those who receive this continuous preventive healthcare really live healthier, longer, and that the overall societal costs are lower. If Neko can prove this, it will no longer just be a health check company. It may truly establish a new: Preventive Healthcare Operating System. And that would be the real "Apple moment" in the healthcare industry.